Celgene
BMS faces lawsuit for allegedly extending Pomalyst monopoly with fraudulent patents and payoffs
Anika Sharma
Bristol Myers Squibb (BMS) and Celgene’s widely-used multiple myeloma treatment, Pomalyst, has found itself entangled in a legal battle after ...
